Leap Therapeutics Inc (NASDAQ:LPTX) shares, rose in value, with the stock price down by -1.52% to the previous day’s close as strong demand from buyers drove the stock to $0.36.
Actively observing the price movement in the last trading, the stock closed the session at $0.37, falling within a range of $0.35 and $0.3748. The value of beta (5-year monthly) was 0.211. Referring to stock’s 52-week performance, its high was $4.79, and the low was $0.22. On the whole, LPTX has fluctuated by -12.43% over the past month.
With the market capitalization of Leap Therapeutics Inc currently standing at about $14.99 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-25.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LPTX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of LPTX currently trading nearly 7.21% and -11.62% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.31, while the 7-day volatility ratio is showing 11.46% which for the 30-day chart, stands at 17.21%. Furthermore, Leap Therapeutics Inc (LPTX)’s beta value is -0.23, and its average true range (ATR) is 0.05.
A comparison of Leap Therapeutics Inc (LPTX) with its peers suggests the former has fared considerably weaker in the market. LPTX showed an intraday change of -1.52% in last session, and over the past year, it shrunk by -87.81%%.
Data on historical trading for Leap Therapeutics Inc (NASDAQ:LPTX) indicates that the trading volumes over the past 10 days have averaged 0.42 and over the past 3 months, they’ve averaged 2.59 million. According to company’s latest data on outstanding shares, there are 38.33 million shares outstanding.
Nearly 25.81% of Leap Therapeutics Inc’s shares belong to company insiders and institutional investors own 28.13% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.81 million shares as on 2025-03-31, resulting in a short ratio of 0.72. According to the data, the short interest in Leap Therapeutics Inc (LPTX) stood at 1084.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 1.89 million. The stock has fallen by -87.36% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LPTX stock heading into the next quarter.
